Chlorozotocin: Phase II evaluation in patients with advanced sarcomas

P. P. Sordillo, G. B. Magill, R. J. Gralla

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Chlorozotocin is a water-soluble nitrosourea with high alkylating and low carbamoylating activities; it has demonstrated activity in several animal tumor systems including B16 melanoma and L1210 leukemia. Occasional responses have been noted in patients with lymphoma, Hodgkin's disease, melanoma, and carcinomas of the colon, breast, and ovary. Published phase II studies of chlorozotocin used against carcinomas of the lung and kidney have shown minimal activity. A phase II trial of this agent was undertaken to assess its activity against soft tissue sarcomas.

Original languageEnglish (US)
Pages (from-to)513-514
Number of pages2
JournalCancer Treatment Reports
Volume65
Issue number5-6
StatePublished - Dec 1 1981

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chlorozotocin: Phase II evaluation in patients with advanced sarcomas'. Together they form a unique fingerprint.

  • Cite this

    Sordillo, P. P., Magill, G. B., & Gralla, R. J. (1981). Chlorozotocin: Phase II evaluation in patients with advanced sarcomas. Cancer Treatment Reports, 65(5-6), 513-514.